ISSN Print 2500–1094
ISSN Online 2542–1204
Bulletin of RSMU
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
ORIGINAL RESEARCH
Borderline ovarian tumors in pregnancy
About authors
1 Family Planning and Reproduction Center, Moscow, Russia
2 Pirogov Russian National Research Medical University, Moscow, Russia
Correspondence should be addressed: Pyotr A. Klimenko
Sevastopolsky prospect, 24а, Moscow, 117209; ur.liam@oknemilk.ap
About paper
Compliance with ethical standards: the study was approved by the Ethics Committee of Pirogov Russian National Research Medical University (protocol № 176 dates June 25, 2018). The informed consent was submitted by all study participants.
Author contribution: all authors contributed to the research and manuscript preparation equally, read the approved the final version of the article before publishing.
Received: 2020-04-07
Accepted: 2020-04-21
Published online: 2020-04-27
|
Fig. 1. Ovarian tumors/tumor-like formations distribution in accordance with the histological structure, stage (BOTs/ malignant ovarian tumors) and abnormality degree
(ovarian cancer)
Fig. 2. Morphology of BOTs and malignant ovarian tumors in pregnant women. А. Borderline serous ovarian cystadenoma (×10, hematoxylin and eosin staining). B. Poorly differentiated serous ovarian carcinoma (×10, hematoxylin and eosin staining). C. Borderline mucinous ovarian cystadenoma (×10, hematoxylin and eosin staining). D. Mucinous ovarian carcinoma (×10, hematoxylin and eosin staining).
Fig. 3. CD31 expression in the malignant ovarian tumor (×20). Vessels are
marked with arrows
Fig. 4. CD31 expression in the borderline ovarian tumor (×20). Vessels are marked with arrows
